4536 — Santen Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥524bn
- ¥515bn
- ¥300bn
- 88
- 48
- 87
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.28 | ||
| PEG Ratio (f) | 2.23 | ||
| EPS Growth (f) | 6.85% | ||
| Dividend Yield (f) | 2.49% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.91 | ||
| Price to Tang. Book | 2.66 | ||
| Price to Free Cashflow | 17.35 | ||
| Price to Sales | 1.8 | ||
| EV to EBITDA | 8.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.97% | ||
| Return on Equity | 11.15% | ||
| Operating Margin | 14.04% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 249,605 | 266,257 | 279,037 | 301,965 | 300,004 | 292,278 | 300,462 | 4.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1.49 | -10.17 | -59.72 | +313.78 | -0.11 | -4.41 | +13.29 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Santen Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, and sale of pharmaceuticals. The Company engages in global research and development, manufacture, sale, and marketing of pharmaceuticals in the ophthalmology field. The Company engages in prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other businesses. The Company operates in Japan, Asia, Europe, the Middle East, and Africa (EMEA), China, and other regions.
Directors
- Akira Kurokawa CHM (68)
- Shigeo Taniuchi PRE (47)
- Kazuo Koshiji CFO
- Minoru Hara CIO
- Mika Masunari CCO
- Takeshi Ito SME (62)
- Akio Kimura MEO
- Satoshi Suzuki MEO
- Shinichi Teramachi DSL
- Ippei Kurihara DMK
- Tomo Yashiki DHR
- Ken Araki EXO
- Frank Binder EXO
- Luis Iglesias EXO
- Tatsuya Kaihara EXO
- Kenji Morishima EXO
- Takahiro Morita EXO
- Peter Sallstig EXO
- Isao Takahashi EXO
- Takayuki Yamada EXO
- Kunihito Minakawa IND (67)
- Kanoko Oishi IND (60)
- Yutaro Shintaku IND (66)
- Last Annual
- March 31st, 2025
- Last Interim
- September 30th, 2025
- Incorporated
- July 4th, 1925
- Public Since
- November 4th, 1963
- No. of Shareholders
- 24,124
- No. of Employees
- 3,849
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 324,833,723
- Address
- 3-9-19, Shimo-Shinjo, Higashiyodogawa-ku, OSAKA-SHI, 530-8552
- Web
- https://www.santen.com/
- Phone
- +81 676648621
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4536
Dividend For 4536.T - 19.0000 JPY
Full Year 2026 Santen Pharmaceutical Co Ltd Earnings Release
Similar to 4536
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Santen Pharmaceutical Co share price?
As of Today at 22:05 UTC, shares in Santen Pharmaceutical Co are trading at ¥1,612. This share price information is delayed by 15 minutes.
How has the Santen Pharmaceutical Co share price performed this year?
Shares in Santen Pharmaceutical Co last closed at ¥1,612 and the price had moved by -3.13% over the past 365 days. In terms of relative price strength the Santen Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -24.24% over the past year.
What are the analyst and broker recommendations for Santen Pharmaceutical Co?
The overall consensus recommendation for Santen Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Santen Pharmaceutical Co dividend yield?
The Santen Pharmaceutical Co dividend yield is 2.36% based on the trailing twelve month period.
Does Santen Pharmaceutical Co pay a dividend?
Last year, Santen Pharmaceutical Co paid a total dividend of ¥38, and it currently has a trailing dividend yield of 2.36%.Looking ahead, shares in Santen Pharmaceutical Co are due to go ex-dividend on 2026-03-30 and the next dividend pay date is 2025-11-28.
When does Santen Pharmaceutical Co next pay dividends?
Santen Pharmaceutical Co are due to go ex-dividend on 2026-03-30 and the next dividend pay date is 2025-11-28. The historic dividend yield on Santen Pharmaceutical Co shares is currently 2.36%.
How do I buy Santen Pharmaceutical Co shares?
To buy shares in Santen Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Santen Pharmaceutical Co?
As of the previous close price of ¥1,612, shares in Santen Pharmaceutical Co had a market capitalisation of ¥524bn.
Where are Santen Pharmaceutical Co shares listed?
Here are the trading details for Santen Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4536
What kind of share is Santen Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Santen Pharmaceutical Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Santen Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Santen Pharmaceutical Co is ¥2,063. That is 27.95% above the last closing price of ¥1,612.
Analysts covering Santen Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥104 for the next financial year.
Find out moreWhat is the trend in the Santen Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Santen Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -20.8%.
As of the last closing price of ¥1,612, shares in Santen Pharmaceutical Co were trading +4.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Santen Pharmaceutical Co PE Ratio?
The Santen Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 14.28. The shares last closed at ¥1,612.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Santen Pharmaceutical Co?
Santen Pharmaceutical Co's management team is headed by:
- Akira Kurokawa - CHM
- Shigeo Taniuchi - PRE
- Kazuo Koshiji - CFO
- Minoru Hara - CIO
- Mika Masunari - CCO
- Takeshi Ito - SME
- Akio Kimura - MEO
- Satoshi Suzuki - MEO
- Shinichi Teramachi - DSL
- Ippei Kurihara - DMK
- Tomo Yashiki - DHR
- Ken Araki - EXO
- Frank Binder - EXO
- Luis Iglesias - EXO
- Tatsuya Kaihara - EXO
- Kenji Morishima - EXO
- Takahiro Morita - EXO
- Peter Sallstig - EXO
- Isao Takahashi - EXO
- Takayuki Yamada - EXO
- Kunihito Minakawa - IND
- Kanoko Oishi - IND
- Yutaro Shintaku - IND